| $337M | ||
| $259M | ||
| $100M | ||
| $79M | ||
| $60M | ||
| $58M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Theriva Biologics Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. The company was formerly known as Synthetic Biologics, Inc. and changed its name to Theriva Biologics Inc. in October 2022. Theriva Biologics Inc. is headquartered in Rockville, Maryland.
Over the last 12 months, insiders at Theriva Biologics, Inc. have bought $0 and sold $0 worth of Theriva Biologics, Inc. stock.
On average, over the past 5 years, insiders at Theriva Biologics, Inc. have bought $159,974 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 14,000 shares for transaction amount of $9,703 was made by SHALLCROSS STEVEN A (CEO and CFO) on 2023‑06‑07.
| 2023-06-07 | SHALLCROSS STEVEN A | CEO and CFO | 14,000 0.2422% | $0.69 | $9,703 | -31.14% | ||
| 2023-06-06 | SHALLCROSS STEVEN A | CEO and CFO | 26,000 0.4106% | $0.63 | $16,453 | -24.34% | ||
| 2023-02-10 | SHALLCROSS STEVEN A | CEO and CFO | 25,000 0.6508% | $1.04 | $26,075 | -41.29% | ||
| 2023-02-02 | SHALLCROSS STEVEN A | CEO and CFO | 25,000 0.5868% | $0.94 | $23,513 | -33.28% | ||
| 2023-01-25 | SHALLCROSS STEVEN A | CEO and CFO | 25,000 0.5447% | $0.87 | $21,825 | -25.71% | ||
| 2023-01-20 | SHALLCROSS STEVEN A | CEO and CFO | 25,000 0.4668% | $0.75 | $18,705 | -16.20% | ||
| 2022-12-29 | SHALLCROSS STEVEN A | CEO and CFO | 100,000 1.0907% | $0.44 | $43,700 | +41.74% |
| SHALLCROSS STEVEN A | CEO and CFO | 250000 2.7596% | $124,250.00 | 7 | 0 | <0.0001% |
$13,665,147 | 42 | -70.74% | $2.53M | |
$1,138,733 | 28 | -4.94% | $5.09M | |
$47,363 | 28 | -14.61% | $4.29M | |
$613,181 | 18 | -20.90% | $5.61M | |
$1,556,551 | 15 | -25.43% | $5.82M | |
$742,412 | 14 | -50.36% | $5.14M | |
$139,855 | 11 | -32.84% | $5.16M | |
$111,748 | 9 | -47.72% | $5.01M | |
$100,375 | 8 | -51.85% | $3.83M | |
Theriva Biologics, Inc. (TOVX) | $159,974 | 7 | -18.60% | $4.5M |
$46,740 | 5 | -73.90% | $3.67M | |
$115,514 | 4 | -94.89% | $3.92M | |
$76,299 | 4 | 11.60% | $6.74M | |
$726,438 | 4 | -72.85% | $5.22M | |
$37,465 | 3 | -40.67% | $2.72M | |
$14,530 | 3 | 62.23% | $4.44M | |
$53,042 | 3 | -44.40% | $3.36M | |
$739,010 | 1 | 3.33% | $4.11M | |
$1,049,630 | 1 | -74.91% | $4.65M |
| Increased Positions | 5 | +35.71% | 174,340 | +505.71% |
| Decreased Positions | 5 | -35.71% | 18,126 | -52.58% |
| New Positions | 4 | New | 174,319 | New |
| Sold Out Positions | 3 | Sold Out | 9,161 | Sold Out |
| Total Postitions | 14 | 0% | 190,688 | +453.14% |
| Ubs Group Ag | $23.00 | 0.55% | 16,406 | -1,445 | -8.1% | 2024-12-31 |
| Citigroup Inc | $11.00 | 0.26% | 7,756 | +7,756 | New | 2024-12-31 |
| Blackrock, Inc. | $10.00 | 0.25% | 7,568 | 0 | 0% | 2025-03-31 |
| Tower Research Capital Llc (Trc) | $2.00 | 0.05% | 1,391 | +730 | +110.44% | 2024-12-31 |
| Osaic Holdings, Inc. | $2.00 | 0.04% | 1,294 | 0 | 0% | 2024-12-31 |
| Bank Of America Corp /De/ | $0 | <0.01% | 20 | +11 | +122.22% | 2024-12-31 |
| Ifp Advisors, Inc | $0 | 0% | 11 | -296 | -96.42% | 2024-12-31 |
| Sbi Securities Co., Ltd. | $0 | 0% | 10 | 0 | 0% | 2025-03-31 |
| Planning Capital Management Corp | $0 | 0% | 4 | 0 | 0% | 2024-09-30 |
| Anson Funds Management Lp | $0 | 0% | 0 | -139,046 | Sold Out | 2024-12-31 |